Ben Alkahe

Title: Ben Alkahe: Innovator in Glycan-Modified Receptors and Hepatitis B Research

Introduction

Ben Alkahe is a notable inventor based in Tel Aviv, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of glycan-modified soluble receptors and methods for inhibiting the release of hepatitis B virus from liver cells. With a total of 2 patents, Alkahe's work has the potential to impact medical treatments and therapies.

Latest Patents

Alkahe's latest patents include two innovative inventions. The first patent is titled "Glycan modified soluble receptors and binding protein and their use." This invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein, or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc, or GalNAc. The second patent is "Method for inhibiting release of hepatitis B virus from liver cells." This invention focuses on the use of the soluble LDL receptor (sLDLR) in viral hepatitis, providing a potential therapeutic avenue for managing this viral infection.

Career Highlights

Throughout his career, Ben Alkahe has worked with Yeda Research and Development Company, where he has been able to apply his innovative ideas in a collaborative research environment. His work has contributed to advancements in understanding and treating viral infections and related health issues.

Collaborations

Alkahe has collaborated with notable colleagues such as Menachem Rubinstein and Ariel Werman. These partnerships have likely enhanced the scope and impact of his research endeavors.

Conclusion

Ben Alkahe's contributions to the field of biotechnology through his patents and collaborations highlight his role as an innovator in medical research. His work continues to pave the way for advancements in treatments for viral infections and related health challenges.